RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Antibe Therapeutics Stock

Antibe Therapeutics EBIT 2025

Antibe Therapeutics EBIT

-29.4 M CAD

Ticker

ATE.TO

ISIN

CA0370255097

WKN

A2QJPN

In 2025, Antibe Therapeutics's EBIT was -29.4 M CAD, a 22.2% increase from the -24.06 M CAD EBIT recorded in the previous year.

The Antibe Therapeutics EBIT history

YEAREBIT (undefined CAD)
2030e-
2029e13.77
2028e-4.33
2027e-25.3
2026e-1.97
2025e-29.4
2024e-24.06
2023-20.54
2022-25.62
2021-25.72
2020-17.48
2019-12.39
2018-6.66
2017-5.21
2016-3.15
2015-4.4
2014-2.68
2013-1.05
2012-0.94
2011-0.6
2010-1.31

Antibe Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Antibe Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Antibe Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Antibe Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Antibe Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Antibe Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Antibe Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Antibe Therapeutics’s growth potential.

Antibe Therapeutics Revenue, EBIT and net profit per share

DateAntibe Therapeutics RevenueAntibe Therapeutics EBITAntibe Therapeutics Net Income
2030e64.32 M undefined0 undefined32.65 M undefined
2029e40.75 M undefined13.77 M undefined12.64 M undefined
2028e21.78 M undefined-4.33 M undefined-4.21 M undefined
2027e0 undefined-25.3 M undefined-24.75 M undefined
2026e12.98 M undefined-1.97 M undefined-2.08 M undefined
2025e0 undefined-29.4 M undefined-27.99 M undefined
2024e0 undefined-24.06 M undefined-22.45 M undefined
20230 undefined-20.54 M undefined-19.48 M undefined
20220 undefined-25.62 M undefined-25.06 M undefined
20219.71 M undefined-25.72 M undefined-26.3 M undefined
20209.67 M undefined-17.48 M undefined-19.34 M undefined
20199.54 M undefined-12.39 M undefined-12.82 M undefined
20188.51 M undefined-6.66 M undefined-7.43 M undefined
20179.05 M undefined-5.21 M undefined-5.75 M undefined
20164.43 M undefined-3.15 M undefined-3.36 M undefined
201520,000 undefined-4.4 M undefined-4.4 M undefined
201410,000 undefined-2.68 M undefined-2.68 M undefined
20130 undefined-1.05 M undefined-1.05 M undefined
20120 undefined-940,000 undefined-940,000 undefined
20110 undefined-600,000 undefined-600,000 undefined
20100 undefined-1.31 M undefined-1.31 M undefined

Antibe Therapeutics stock margins

The Antibe Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Antibe Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Antibe Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Antibe Therapeutics's sales revenue. A higher gross margin percentage indicates that the Antibe Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Antibe Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Antibe Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Antibe Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Antibe Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Antibe Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Antibe Therapeutics Margin History

Antibe Therapeutics Gross marginAntibe Therapeutics Profit marginAntibe Therapeutics EBIT marginAntibe Therapeutics Profit margin
2030e36.56 %0 %50.76 %
2029e36.56 %33.79 %31.02 %
2028e36.56 %-19.86 %-19.35 %
2027e36.56 %0 %0 %
2026e36.56 %-15.14 %-16.03 %
2025e36.56 %0 %0 %
2024e36.56 %0 %0 %
202336.56 %0 %0 %
202236.56 %0 %0 %
202136.56 %-264.88 %-270.85 %
202038.26 %-180.77 %-200 %
201937.21 %-129.87 %-134.38 %
201839.72 %-78.26 %-87.31 %
201743.43 %-57.57 %-63.54 %
201646.28 %-71.11 %-75.85 %
201536.56 %-22,000 %-22,000 %
201436.56 %-26,800 %-26,800 %
201336.56 %0 %0 %
201236.56 %0 %0 %
201136.56 %0 %0 %
201036.56 %0 %0 %

Antibe Therapeutics Aktienanalyse

What does Antibe Therapeutics do?

Antibe Therapeutics Inc is a biopharmaceutical company specializing in the development of novel treatment methods for inflammation and pain. The Canadian company was founded in 2009 and is headquartered in Toronto, Ontario. Antibe Therapeutics has made a name for itself in the pharmaceutical industry through its innovative technologies and compounds. The business model of Antibe Therapeutics is based on the discovery and development of new compounds based on non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medications for the treatment of inflammation and pain. However, Antibe Therapeutics has developed a promising method to optimize the compounds of NSAIDs and minimize their side effects. The company is divided into three divisions to organize its products and services. The first division is the analgesic pipeline, which focuses on the research and development of neuromodulation programs for the treatment of pain and inflammation. Antibe Therapeutics' neuromodulation technology aims to target specific receptor systems to treat inflammation and pain specifically. The second division is the GI Safety Inhibition Concept, which offers a novel anti-inflammatory technology for the treatment of pain and inflammation with improved gastrointestinal tolerability. This technology aims to minimize the side effects of NSAIDs, particularly in the gastrointestinal system. The third division is the clinical development, which conducts clinical trials for new medications. Antibe Therapeutics has a number of drugs in clinical development, including ATB-346, which is considered a novel anti-inflammatory and pain-reducing medication for patients with arthritis and other inflammatory conditions. Another important product of Antibe Therapeutics is the fully synthesized hydroxyliminodiazole molecule (ATB-352), which is used for the treatment of neuropathic pain. The company believes that ATB-352 offers promising benefits over conventional pain medications and represents an effective treatment option for patients with chronic pain. Antibe Therapeutics has established several partnerships with major pharmaceutical companies in the past to advance the development and commercialization of its products. In 2020, Antibe Therapeutics entered into an agreement with Nuance Pharma, a leading Chinese company in the development and commercialization of anesthetics, to market ATB-346 in China and adjacent areas. This partnership provides Antibe Therapeutics with access to the rapidly growing markets in Asia and also strengthens its position as a global company. Overall, Antibe Therapeutics has found a valuable place in the pharmaceutical industry through its innovation and ability to focus on the areas of inflammation and pain. With a strong pipeline and a variety of promising product candidates, Antibe Therapeutics believes it is able to improve the lives of millions of people worldwide by providing safer and more effective treatment methods for inflammation and pain. Antibe Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Antibe Therapeutics's EBIT

Antibe Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Antibe Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Antibe Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Antibe Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Antibe Therapeutics stock

How much did Antibe Therapeutics achieve in EBIT for the current year?

In the current year, Antibe Therapeutics has achieved an EBIT of -29.4 M CAD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Antibe Therapeutics.

How has the EBIT of Antibe Therapeutics developed in recent years?

The EBIT of Antibe Therapeutics has increased by 22.204% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Antibe Therapeutics?

The EBIT of Antibe Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Antibe Therapeutics pay?

Over the past 12 months, Antibe Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antibe Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Antibe Therapeutics?

The current dividend yield of Antibe Therapeutics is .

When does Antibe Therapeutics pay dividends?

Antibe Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Antibe Therapeutics?

Antibe Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Antibe Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Antibe Therapeutics located?

Antibe Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Antibe Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Antibe Therapeutics from 7/21/2025 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 7/21/2025.

When did Antibe Therapeutics pay the last dividend?

The last dividend was paid out on 7/21/2025.

What was the dividend of Antibe Therapeutics in the year 2024?

In the year 2024, Antibe Therapeutics distributed 0 CAD as dividends.

In which currency does Antibe Therapeutics pay out the dividend?

The dividends of Antibe Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Antibe Therapeutics

Our stock analysis for Antibe Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antibe Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.